According to Janelidze et al. [89], considering the tau PET prediction, CSF p-tau217 correlates better than CSF p-tau181 with CSF Aβ42 and the retention of [18F] flortaucipir and [18F] flutemetamol, two radiopharmaceuticals used to visualize brain pathologies in AD on PET scans [89]. The gene discussed is MAPT; the disease is Alzheimer disease.